EMEA-001191-PIP01-11-M03

Key facts

Invented name
Daklinza
Active substance
Daclatasvir
Therapeutic area
Infectious diseases
Decision number
P/0367/2019
PIP number
EMEA-001191-PIP01-11-M03
Pharmaceutical form(s)
  • Chewable tablet
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of chronic hepatitis C
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

Tel. +44 (0)1895 523740
E-mail: medical.information@bms.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating